Abstract:Aerobic glycolysis, also known as the Warburg effect, is a hallmark of cancer cell glucose metabolism and plays a crucial role in the activation of various types of immune cells. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) catalyzes the conversion of D-glyceraldehyde 3-phosphate to D-glycerate 1,3-bisphosphate in the 6th critical step in glycolysis. GAPDH exerts metabolic flux control during aerobic glycolysis and therefore is an attractive therapeutic target for cancer and autoimmune diseases. Recently, GAPDH inhibitors were reported to function through common suicide inactivation by covalent binding to the cysteine catalytic residue of GAPDH. Herein, by developing a high-throughput enzymatic screening assay, we discovered that the natural product 1,2,3,4,6-penta-O-galloyl-β-D-glucopyranose (PGG) is an inhibitor of GAPDH with Ki = 0.5 μM. PGG blocks GAPDH activity by a reversible and NAD+ and Pi competitive mechanism, suggesting that it represents a novel class of GAPDH inhibitors. In-depth hydrogen deuterium exchange mass spectrometry (HDX-MS) analysis revealed that PGG binds to a region that disrupts NAD+ and inorganic phosphate binding, resulting in a distal conformational change at the GAPDH tetramer interface. In addition, structural modeling analysis indicated that PGG probably reversibly binds to the center pocket of GAPDH. Moreover, PGG inhibits LPS-stimulated macrophage activation by specific downregulation of GAPDH-dependent glucose consumption and lactate production. In summary, PGG represents a novel class of GAPDH inhibitors that probably reversibly binds to the center pocket of GAPDH. Our study sheds new light on factors for designing a more potent and specific inhibitor of GAPDH for future therapeutic applications.

Current status and progress of research on the ADP-dependent glucokinase gene

Phosphoenolpyruvate Carboxykinase in Cell Metabolism: Roles and Mechanisms Beyond Gluconeogenesis.

Structural basis for ADP-dependent glucokinase inhibition by 8-bromo–substituted adenosine nucleotide

Current Insight on the Role of Glucokinase and Glucokinase Regulatory Protein in Diabetes

Clinical investigation of glucokinase activators for the restoration of glucose homeostasis in diabetes

Glucokinase (GCK) in diabetes: from molecular mechanisms to disease pathogenesis

The role of glucose-6-phosphatase activity in glucose homeostasis and its potential for diabetes therapy

Insights to the emerging potential of glucokinase activators as antidiabetic agent

Glucokinase and Glucokinase Activator

Recent findings in the regulation of G6PD and its role in diseases

Lys169 of Human Glucokinase is a Determinant for Glucose Phosphorylation: Implication for the Atomic Mechanism of Glucokinase Catalysis.

A patent review of glucokinase activators and disruptors of the glucokinase – glucokinase regulatory protein interaction: 2011 – 2014

Phosphorylation of cytosolic hPGK1 affects protein stability and ligand binding: implications for its subcellular targeting in cancer

Identification of a Novel Non-Atp-competitive Protein Kinase Inhibitor of PGK1 from Marine Nature Products.

Evolution of Glucose Utilization: Glucokinase and Glucokinase Regulator Protein

GlucoKinaseDB: A comprehensive, curated resource of glucokinase modulators for clinical and molecular research

6-Phosphogluconate dehydrogenase promotes glycolysis and fatty acid synthesis by inhibiting the AMPK pathway in lung adenocarcinoma cells

Natural product 1,2,3,4,6-penta-O-galloyl-β-D-glucopyranose is a reversible inhibitor of glyceraldehyde 3-phosphate dehydrogenase

Recent advances in pyruvate dehydrogenase kinase inhibitors: Structures, inhibitory mechanisms and biological activities

Targeting human Glucokinase for the treatment of type 2 diabetes: an overview of allosteric Glucokinase activators

A retrospective overview of PHGDH and its inhibitors for regulating cancer metabolism